Arbutus Biopharma Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Arbutus Biopharma kazanç ve gelirinin sırasıyla yıllık 11.7% ve 44.2% oranında artması tahmin edilirken, EPS'nin yıllık 14.5% oranında büyümesi bekleniyor.

Anahtar bilgiler

11.7%

Kazanç büyüme oranı

14.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	44.2%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	20 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Jul 05

Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up

May 23

Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 03

Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Nov 09

Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

Oct 24

We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow

Apr 26

Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher

Nov 11

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Oct 28

Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'

Sep 12

Arbutus stock rises on US patent linked to hepatitis B therapy AB-729

Aug 30

Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Aug 06

Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial

Jul 20

Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release

Jun 29

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

Jun 15

Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic

May 11

Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues

Mar 08

Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest

Mar 07

Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?

Dec 17

Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Dec 14

Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment

Nov 20

Arbutus Biopharma: A First Assessment

Sep 15

We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate

Sep 11

Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment

Jun 29

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:ABUS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	8	-81	N/A	N/A	1
12/31/2025	5	-69	N/A	N/A	5
12/31/2024	6	-73	N/A	N/A	5
9/30/2024	7	-77	-72	-72	N/A
6/30/2024	10	-77	-73	-73	N/A
3/31/2024	13	-74	-79	-78	N/A
12/31/2023	18	-73	-87	-86	N/A
9/30/2023	22	-75	-87	-86	N/A
6/30/2023	24	-73	-84	-83	N/A
3/31/2023	33	-70	-84	-83	N/A
12/31/2022	39	-69	-36	-35	N/A
9/30/2022	36	-69	-38	-38	N/A
6/30/2022	33	-76	-36	-35	N/A
3/31/2022	21	-85	-30	-29	N/A
12/31/2021	11	-88	-68	-68	N/A
9/30/2021	10	-87	-64	-63	N/A
6/30/2021	8	-84	-60	-59	N/A
3/31/2021	8	-79	-54	-54	N/A
12/31/2020	7	-76	-52	-51	N/A
9/30/2020	6	-83	-50	-50	N/A
6/30/2020	8	-147	-61	-61	N/A
3/31/2020	7	-156	-70	-70	N/A
12/31/2019	6	-165	-72	-71	N/A
9/30/2019	6	-158	-75	-75	N/A
6/30/2019	5	-100	-65	-64	N/A
3/31/2019	5	-73	-65	-64	N/A
12/31/2018	6	-67	-69	-68	N/A
9/30/2018	7	-83	-62	-61	N/A
6/30/2018	12	-68	N/A	-64	N/A
3/31/2018	12	-86	N/A	-51	N/A
12/31/2017	11	-85	N/A	-49	N/A
9/30/2017	8	-267	N/A	-53	N/A
6/30/2017	2	-275	N/A	-52	N/A
3/31/2017	1	-387	N/A	-64	N/A
12/31/2016	1	-384	N/A	-58	N/A
9/30/2016	14	-171	N/A	-60	N/A
6/30/2016	18	-180	N/A	-47	N/A
3/31/2016	21	-65	N/A	-48	N/A
12/31/2015	23	-63	N/A	-56	N/A
9/30/2015	17	-62	N/A	-45	N/A
6/30/2015	17	-42	N/A	-49	N/A
3/31/2015	15	-33	N/A	-39	N/A
12/31/2014	15	-39	N/A	-12	N/A
9/30/2014	18	-35	N/A	-3	N/A
6/30/2014	17	-33	N/A	0	N/A
3/31/2014	18	-30	N/A	5	N/A
12/31/2013	15	-14	N/A	-7	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ABUS önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: ABUS önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: ABUS önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: ABUS şirketinin gelirinin (yıllık 44.2% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ABUS şirketinin gelirinin (yıllık 44.2% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ABUS 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Arbutus Biopharma Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates fall by 12%

Consensus revenue estimates decrease by 11%

Consensus revenue estimates fall by 28%

Consensus revenue estimates decrease by 11%, EPS upgraded

Consensus estimates of losses per share improve by 24%

Consensus revenue estimates increase by 40%

Recent updates

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Consensus revenue estimates fall by 12%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Arbutus Biopharma Corporation to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Arbutus Biopharma Corporation to Report Q2, 2024 Results on Aug 01, 2024

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Arbutus Biopharma Corporation Announces New Preliminary End-Of- Treatment Data from the Phase 2A Clinical Trial

Arbutus Biopharma Corporation Announces New Data from its Phase 2a Clinical Trial IM-PROVE I (AB-729-201)

Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up

Whitefort Capital Management Sends an Open Letter to Shareholders of Arbutus Biopharma

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders

Whitefort Capital Management Engages with Arbutus Biopharma

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Arbutus Biopharma Corporation Announces Retirement of Chief Scientific Officer, Michael J. Sofia Effective December 31, 2024

Moderna Investors Should Beware Patent-Dispute Fallout

Arbutus Biopharma Corporation to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Corporation, Annual General Meeting, May 22, 2024

Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains

Consensus revenue estimates decrease by 11%

Consensus revenue estimates fall by 28%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Arbutus Biopharma Corporation to Report Q4, 2023 Results on Feb 29, 2024

Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline

Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD

Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Arbutus Biopharma Corporation Announces CEO Changes

Arbutus Biopharma Corporation Announces CEO Changes

Arbutus Biopharma Corporation to Report Q3, 2023 Results on Nov 07, 2023

Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

Arbutus Biopharma Corporation Announces Pipeline Updates and Dosing of First Subject in Phase 1a/1b Clinical Trial with AB-101

Consensus revenue estimates decrease by 11%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Arbutus Biopharma Corporation to Report Q2, 2023 Results on Aug 03, 2023

Arbutus Biopharma Corporation Announces the Appointment of Melissa V. Rewolinski to Its Board of Directors

Arbutus Biopharma Corporation Appoints Two New Executives

Arbutus Biopharma Corporation Appoints Two New Executives

Arbutus Doses First Patient in Additional Treatment Arm of Phase 2A Triple Combination Clinical Trial That Includes A Pd-1 Monoclonal Antibody

Arbutus Biopharma Corporation to Present AB-729 and AB-836 Data at EASL Congress 2023

Consensus estimates of losses per share improve by 24%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arbutus Biopharma Corporation Announces Resignation of Tram Tran from the Board of Directors, Effective on February 26, 2023

Arbutus Biopharma Corporation to Report Q4, 2022 Results on Mar 02, 2023

Arbutus Biopharma Corporation Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

Insufficient new directors

Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Arbutus Biopharma Corporation Appoints Mike Mcelhaugh as Chief Operating Officer, Effective as of November 1, 2022

Arbutus Biopharma Corporation Announces Resignation of Gaston Picchio as Chief Development Officer

Arbutus Biopharma Corporation to Report Q3, 2022 Results on Nov 03, 2022

Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'

Arbutus stock rises on US patent linked to hepatitis B therapy AB-729

Consensus revenue estimates increase by 40%

Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arbutus Biopharma Corporation to Report Q2, 2022 Results on Aug 04, 2022

Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with Ab-729 and Capsid Inhibitor

Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial

Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release

Arbutus Biopharma Corporation Presents New Data on AB-729, Ab-836 and AB-101 At the EASL International Liver Congress™ 2022 and Provides Ab-836 Clinical Update

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

Arbutus Biopharma Corporation and Vaccitech plc Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Insufficient new directors

Consensus revenue estimates increase by 57%